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Introduction
Non-muscle invasive bladder cancer (NMIBC) represents 
approximately 75% of newly diagnosed bladder cancers 
(BCa) in western countries (1). Patients with NMIBC have 
a relatively favorable prognosis, with ten-years cancer-
specific survival (CSS) rates varying between 75% and 
100%, depending on tumor grade (2). Nevertheless, despite 
adequate therapy, patients with NMIBC have a life-long risk 
of disease recurrence and, more importantly, of progression 
to muscle-invasive bladder cancer (MIBC) (3). While 
cancer recurrence mainly impacts our patients’ quality of 
life and the economical burden of the disease, progression 
to MIBC represents a dramatic event, significantly lowering 
survival probability and calling for intensified therapy 
such as radical cystectomy (4). Indeed, patients harboring 
a NMIBC that eventually progress to MIBC have a worse 
survival probability compared to a patient who presents 
with a primary MIBC (5). Because of these reasons, 
predicting both disease recurrence and progression is of 
fundamental importance to accurately stratify patients into 
personalized risk groups for selection of the appropriate 
treatment strategy, which can range from variable follow up 
scheduling, from adjuvant intravesical therapy schemes to 
radical surgery. A personalized assessment of the biologic 
potential and clinical behavior of NMIBC in every specific 
patient could allow for an improvement of oncologic 
outcomes and smart allocation of resources. 
Status quo in the prediction of outcomes in 
NMIBC 
Currently, risk-stratification of patients with NMIBC is 
based on patients’ characteristics and tumor-related features. 
Based on tumor stage, grade, presence of carcinoma in situ 
(CIS), tumor size, tumor number and previous recurrence 
rate, the European Organization for Research and 
Treatment of Cancer (EORTC) risk tables stratify patients 
into low, intermediate and high risk for each disease 
recurrence and progression (6). Since these risk tables were 
built using clinical trial data of patients treated in previous 
decades before the wide spread use of BCG immunotherapy 
and re-TUR, their predictive accuracy is limited in 
contemporary patients. The Spanish Urological Club for 
Oncological Treatment (CUETO) group tried to overcome 
these limitations by including only patients treated with 
BCG and by adding additional features to the model such 
as age and gender (7). However, the discrimination of 
even this nomogram remains unsatisfactory when tested in 
external validation cohorts (8). Both tools exhibited poor 
discrimination for both disease recurrence and progression 
Editorial 
Biomarkers for the prediction of oncologic outcomes in non-
muscle invasive bladder cancer: state of affairs and new frontiers
Francesco Soria1,2, Shahrokh F. Shariat1,3,4,5
1Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 2Division of Urology, Department 
of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy; 3Karl Landsteiner Institute of Urology and 
Andrology, Vienna, Austria; 4Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; 
5Department of Urology, University of Texas Southwestern Medical Center, Dallas, USA
Correspondence to: Shahrokh F. Shariat. Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of 
Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Email: shahrokh.shariat@meduniwien.ac.at.
Provenance: This is an Invited Editorial commissioned by Section Editor Xiao Li (Department of Urology, Jiangsu Cancer Hospital & Jiangsu 
Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China).
Comment on: van Kessel KEM, van der Keur KA, Dyrskjøt L, et al. Molecular Markers Increase Precision of the European Association of Urology 
Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. Clin Cancer Res 2018;24:1586-93. 
Submitted Aug 03, 2018. Accepted for publication Aug 07, 2018.
doi: 10.21037/tau.2018.08.10
View this article at: http://dx.doi.org/10.21037/tau.2018.08.10
755
S754
  Transl Androl Urol 2018;7(Suppl 6):S753-S755tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
Soria and Shariat. Biomarkers for prediction of oncologic outcomes in NMIBC
(0.60 and 0.66, and 0.52 and 0.62, for the EORTC and 
CUETO models, respectively), underlying the need for 
better tools incorporating more powerful predictors of 
oncologic behavior in order to improve NMIBC risk-
stratification and therapy. 
One hope is to fill the “missing information” by 
integrating biomarkers that reflect the biological behavior 
of the cells and its host thereby increasing the capture of 
the tumors personality. To date, several urinary, blood and 
tissue markers have been developed and tested with the 
aim to improving prediction of outcomes and helping with 
selection, thereby moving a step forward towards the era of 
personalized medicine. However, due to their suboptimal 
performances, their role remains, as of today, still limited 
and none of them is currently recommended by expert 
guidelines for daily clinical practice (9). 
Urinary biomarkers have been used to predict short to 
intermediate term oncological outcomes as well as response 
to BCG. A positive fluorescence in situ hybridization (FISH) 
assay, for example, performed at different time points during 
BCG therapy, was associated with either disease persistence 
or recurrence (10,11). Kamat et al. found that a positive 
FISH both at 6 and 12 weeks resection on BCG therapy 
can identify patients at higher risk of disease recurrence 
and progression (12). While promising, validations of these 
findings are still pending. 
Blood-ba sed  b iomarker s  mea sur ing  s y s t emic 
inflammatory response such as the neutrophil-to-
lymphocyte ratio (NLR) and the C-reactive protein (CRP) 
have also been evaluated as predictors of oncological 
outcomes in NMIBC. Their integration into a model for 
the prediction of disease recurrence and progression led 
to an increase in the discrimination of the model (13). 
These biomarkers are interesting as they may be able 
to help patients most likely to benefit from systemic 
immunotherapy such as check-point inhibitors.
A growing body of literature shows that several genes 
and proteins related to different pathways are not only 
involved in bladder carcinogenesis but also in its clinical 
behavior. Consequently, several tissue biomarkers have 
been tested in a multiphased systematic approach (14). 
Even if multiple biomarkers, such as cell-cycle markers 
as well as Ki-67, FGFR3, cadherins, surviving as well 
as immune and inflammation-related biomarkers have 
shown to predict NMIBC outcomes, their prognostic 
value remains suboptimal with only few of them having 
prospective validation study phases (15-20). Recently, van 
Kessel et al. prospectively tested a panel of tissue biomarkers 
comparing their performance to current clinicopathological 
characteristics for risk-stratification (21). Fresh frozen 
tumor samples from 1,239 patients with primary or 
recurrent NMIBC were analyzed for GATA2, TBX2, TBX3 
and ZIC4 methylation and FGFR3, TERT, PIK3CA and RAS 
mutation status. Overall, wild type FGFR3 and methylation 
of GATA2 and TBX3 were significantly associated with 
disease progression; the addition of these selected markers 
to the EORTC risk stratification model increased its 
accuracy and was able to identify a subset of patients at very 
high risk for tumor progression. This is probably clinically 
the most significant finding of this study, as one of the 
major controversies in NMIBC management is to identify 
the patients who are most likely to benefit from intensified 
therapy such as combination systemic therapy or early 
radical cystectomy. 
Conclusions
The search for an ideal biomarker in NMIBC is still 
ongoing. Given the variable and rich mutation landscape, 
branched evolution and intratumor heterogeneity of 
the disease, it is unlikely that a single biomarker is able 
to address the diverse needs of clinicians. Conversely, 
biomarkers panels integrating multiple complementary 
pathways involved in the process of interest (diagnosis, 
staging, prognosis, and/or prediction) could represent a 
breakthrough for patients’ risk stratification and treatment 
selection. Several new biomarkers, probably linked to novel 
therapies such as PD-L1 expression, will soon enter in 
clinical practice helping drive a precision medicine approach 
to BCa. We are slowly but steadily moving towards the era 
of personalized medicine with biomarkers being the traffic 
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